- Home
- MTN vs OCEAW Comparison
MTN vs OCEAW Comparison
Compare MTN & OCEAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTN
- OCEAW
- Stock Information
- Founded
- MTN 1997
- OCEAW N/A
- Country
- MTN United States
- OCEAW United States
- Employees
- MTN N/A
- OCEAW 7
- Industry
- MTN Services-Misc. Amusement & Recreation
- OCEAW Biotechnology: Pharmaceutical Preparations
- Sector
- MTN Consumer Discretionary
- OCEAW Health Care
- Exchange
- MTN Nasdaq
- OCEAW Nasdaq
- Market Cap
- MTN N/A
- OCEAW N/A
- IPO Year
- MTN 1997
- OCEAW 2021
- Fundamental
- Price
- MTN $138.43
- OCEAW $0.02
- Analyst Decision
- MTN Hold
- OCEAW
- Analyst Count
- MTN 9
- OCEAW 0
- Target Price
- MTN $193.33
- OCEAW N/A
- AVG Volume (30 Days)
- MTN 695.0K
- OCEAW N/A
- Earning Date
- MTN 06-05-2025
- OCEAW N/A
- Dividend Yield
- MTN 6.42%
- OCEAW N/A
- EPS Growth
- MTN 10.73
- OCEAW N/A
- EPS
- MTN 6.89
- OCEAW N/A
- Revenue
- MTN $2,946,168,000.00
- OCEAW N/A
- Revenue This Year
- MTN $4.74
- OCEAW N/A
- Revenue Next Year
- MTN $4.20
- OCEAW N/A
- P/E Ratio
- MTN $20.09
- OCEAW N/A
- Revenue Growth
- MTN 3.57
- OCEAW N/A
- 52 Week Low
- MTN $129.85
- OCEAW N/A
- 52 Week High
- MTN $219.84
- OCEAW N/A
- Technical
- Relative Strength Index (RSI)
- MTN 37.58
- OCEAW N/A
- Support Level
- MTN $129.85
- OCEAW N/A
- Resistance Level
- MTN $145.23
- OCEAW N/A
- Average True Range (ATR)
- MTN 6.72
- OCEAW 0.00
- MACD
- MTN -0.98
- OCEAW 0.00
- Stochastic Oscillator
- MTN 25.73
- OCEAW 0.00
About OCEAW Ocean Biomediacal Inc.
Ocean Biomedical Inc is a biopharmaceutical company that is focused on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome.